Program Overview

Aevum Zenth’s Pharmacovigilance division operates as an integrated, end-to-end drug safety ecosystem. Our mandate encompasses the continuous monitoring of medicinal product safety throughout the entire lifecycle—from preclinical development through post-marketing surveillance. We maintain a fully qualified Pharmacovigilance System Master File (PSMF) and execute rigorous Risk Management Plans (RMPs) aligned with global best practices.

Our operations are structured around three core pillars:

  • Case Processing & Management: 24/7 intake and processing of spontaneous reports, literature findings, and clinical trial adverse events with strict adherence to regulatory timelines.
  • Signal Detection & Risk Evaluation: Proactive mining of aggregated safety databases using quantitative and qualitative methodologies to identify emerging safety concerns.
  • Quality Assurance & Auditing: Independent internal audits, vendor oversight, and continuous process improvement validated through annual QPPV (Qualified Person for Pharmacovigilance) reviews.

Regulatory Framework & Compliance

All pharmacovigilance activities are conducted under strict compliance with international standards, including ICH E2A–E2F, WHO-GVP modules, EU Directive 2001/83/EC, and 21 CFR Part 312. Our regional compliance teams maintain direct regulatory liaison channels to ensure real-time alignment with evolving guidance.

United States
FDA (CDER / CBER / CDRH)
✓ Fully Compliant
European Union
EMA / National Competent Authorities
✓ GVP Certified
Japan
PMDA / MHLW
✓ Registered PV Hub
China
NMPA / CDE
✓ Local Entity Approved
Global Health
WHO / ICH
✓ VigiBase Contributor
Canada / APAC
Health Canada / TGA / HKF
✓ Regional Authorization

Global Safety Network

Our distributed pharmacovigilance infrastructure ensures uninterrupted case processing and regulatory reporting across all time zones. Regional safety centers handle localization, medical translation, and authority submissions while centralized analytics teams manage global signal detection.

  • Americas Hub (New York): Primary FDA reporting, US spontaneous intake, and aggregate safety report preparation.
  • EMEA Hub (Dublin): EMA liaison, PSUR/PBRER drafting, EU-GVP implementation, and QPPV oversight.
  • APAC Hub (Singapore): NMPA/PMDA submissions, Asian clinical trial safety monitoring, and regional literature scanning.
  • Global Safety Operations Center (Geneva): 24/7 case triage, expedited reporting coordination, and crisis management.

AI & Data Infrastructure

Aevum Zenth leverages proprietary and enterprise-grade pharmacovigilance technology to accelerate case processing, enhance data quality, and enable predictive safety analytics.

Natural Language Processing (NLP)

Automated extraction and coding of adverse events, concomitant medications, and product names from unstructured spontaneous reports and medical literature.

Real-World Evidence Integration

Continuous ingestion of EHR data, claims databases, and patient registries to support comparative effectiveness and post-marketing safety surveillance.

Blockchain Audit Trails

Immutable logging of all case creation, modification, and submission events to ensure full regulatory transparency and data integrity compliance.

Predictive Signal Analytics

Machine learning models trained on historical safety data to prioritize emerging signals and optimize resource allocation for risk evaluation.

Submission & Reporting Standards

All regulatory submissions adhere to ICH E2B(R3) XML standards and are transmitted via validated direct electronic submission pathways. Aggregate reports are prepared under EU-ARIANE/WHO-ART frameworks.

Report Type Timeline Format / Standard Automation Level
Expedited (Individual Case) 7–15 days post-detection E2B(R3) XML / CIOMS 98% Automated
PSUR / PBRER Quarterly / Annual / Development E2C(R2) / EU-ARIANE Draft Auto-Generated
Deviance Reports Within 14 days of deviation Regulatory Template Manual Review
Literature Findings Continuous / Monthly Batch E2B(R3) / MEDDRA NLP-Assisted

Safety Reporting & Inquiries

Healthcare professionals, patients, and regulatory authorities can submit adverse event reports or request pharmacovigilance documentation through the channels below. All submissions are triaged by licensed clinical pharmacovigilance associates.

24/7 Safety Hotline
+41 22 555 01 99
Email Reporting
safety@aevumzenth.com
Regulatory Submissions Portal
Access Secure Portal →
QPPV & PV Lead
D. Mercer, M.D., Ph.D.